EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application acyclovir oral suspension USP, 200 mg/5 mL. Aurobindo Pharma’s acyclovir oral suspension are an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX (acyclovir), of Mylan Pharmaceuticals Inc.

Acyclovir oral suspension are indicated for acute treatment of herpes zoster (shingles), treatment of initial episodes and the management of recurrent episodes of genital herpes, and treatment of chickenpox (varicella).

Acyclovir oral suspension has an estimated market size of US $10.4 Million for the twelve months ending February 2022, as per IQVIA.